The Center for Biosimilars recaps the top 5 biosimilars articles for the week of January 29, 2018.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 29.
Number 5: At this week’s swearing-in ceremony for Alex Azar, the new Secretary of HHS, President Donald Trump promised that the price of prescription drugs will “come rocketing down” under Azar’s leadership.
Number 4: Celltrion, maker of the biosimilar infliximab product Inflectra, has received a new warning letter from the FDA.
Number 3: A new drug pricing forecast from the consulting company Vizient suggests that biosimilars have reached a tipping point in the US marketplace.
Number 2: The Biosimilars Council has filed an amicus brief in an ongoing case brought by Pfizer against Johnson & Johnson.
Number 1: SB3, a proposed trastuzumab biosimilar developed by Samsung Bioepis, demonstrated equivalence with Herceptin, according to a new study appearing in the Journal of Clinical Oncology.
Finally, last week, our e-newsletter asked whether the FDA should release information from Complete Response Letters. To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.